Back to search results

Sotagliflozin to Prevent Heart Damage from Chemotherapy

This study is testing if a drug called sotagliflozin can prevent heart damage (cardiotoxicity) in people with newly diagnosed lymphoma who are receiving a type of chemotherapy called anthracycline. You might be able to join if you are at least 18 years old, have newly diagnosed lymphoma, and are scheduled to receive a high dose of anthracycline chemotherapy. The study will measure how well your heart pumps blood (Left Ventricular Ejection Fraction or LVEF) using a cardiac MRI to see if sotagliflozin helps protect your heart. The current status of this study is unclear, and it plans to enroll 60 participants.

Study design
This is an interventional study, meaning participants will receive either sotagliflozin or a placebo. It plans to enroll 60 participants.
What's involved
You would start taking sotagliflozin or placebo before your first anthracycline infusion. Your heart's pumping ability will be measured at the beginning of the study and again about one month after your anthracycline treatment is finished, up to 9-10 months later.
Compensation
Not stated in the trial record.
Follow-up
Your heart's pumping ability will be measured one month after completing anthracycline treatment, up to 9-10 months after the study begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07572175

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

Not Yet Recruiting
PHASE2Ages 18+InterventionalPrevention
Icahn School of Medicine at Mount Sinai
~60 participants
Updated 2026-05-07 on ClinicalTrials.gov
What's tested:SotagliflozinPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Left Ventricular Ejection Fraction (LVEF) by Cardiac MRI
Measured over Baseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.

Conditions

Anthracycline-induced Cardiotoxicity
Lymphoma
Chemotherapy
Cardiotoxicity

Explore related trials

Lymphoma

NCT07572175

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Icahn School of Medicine at Mount Sinai

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Carlos G Santos-Gallego, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai
  • Santos-Gallego, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

Carlos G Santos-Gallego, MD
[email protected]
212-241-8484
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients ≥ 18 years
Newly diagnosed lymphoma
Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg/m2)
Eastern Cooperative Oncology Group (ECOG) performance status 0-3

Exclusion

Prior anthracycline treatment
Previous malignancy requiring any chemotherapy or radiotherapy
Previous treatment with SGLT2i (eg due to T2DM) or SGLT1/2i
Previous heart failure (HF patients should already be on SGLT2i as per guidelines)
LVEF\<40% (even in the absence of HF):
Pregnancy or breastfeeding
Standard contraindication to MRI (claustrophobia, non-MRI compatible devices)

What this trial measures

  • Left Ventricular Ejection Fraction (LVEF) by Cardiac MRIBaseline and end of study, one month after completion of anthracycline treatment, up to 9-10 months.

    LVEF is a measure of contractility of the heart (strength of contraction). Normal values are between 55-65%. It is the most widely used parameter by physicians worldwide to measure cardiac contractility.